Enveda raises $311M Series E to push AI-discovered medicines through the clinic

Enveda said it closed a $311 million Series E led by Catalio Capital Management, bringing total capital raised above $845 million, to advance clinical-stage medicines discovered with its PRISM AI platform for chemistry found in nature.

HEALTH desk — Enveda is not pitching another chatbot for doctors; it just parked another nine-figure check behind AI that finds drugs in nature’s chemistry and already has early human data on eczema and metabolic medicines.

Who led, and who joins the board. Catalio Capital Management led the round. In connection with the financing, George Petrocheilos, co-founder and managing partner of Catalio, joined Enveda’s board of directors. A board seat is a governance role. It is not a dollar figure this page prices. On the company page, Petrocheilos said Catalio invests where biotechnology and artificial intelligence meet, and that Enveda is one of the clearest cases of that actually happening. He said that in five years from the Series A, the company turned chemistry that evolution already refined into first-in-class oral medicines for atopic dermatitis, asthma, metabolic disease, and inflammatory bowel disease, and that it built a team that can take those medicines through late-stage development. He said Catalio is proud to lead, and that he looks forward to joining the board. File that quote as the company page’s. BioSpace’s copy of the release prints a different Petrocheilos quote. There he says Enveda is the kind of business Catalio looks for, a full-stack AI-enabled platform from discovery to the clinic, and that three ongoing trials, two already showing therapeutic benefit, validate the platform. Full-stack, and therapeutic benefit, are that BioSpace text. This filing does not merge the two quotes into one speech. A quote is not a patient outcome this desk measured.

Who else wrote checks, in the page’s order. New investors named: Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a notable sovereign wealth fund, and Alderline Group. A sovereign wealth fund is a state investment pool. The page calls this one notable and does not print its name. Do not invent the name. Existing investors who also participated: Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital. The page says Catalio, together with T. Rowe Price Investment Management’s biotechnology team and Surveyor Capital, are among the most experienced healthcare investors, and that Durable Capital Partners, ICONIQ, and Lightspeed have backed technology companies through the internet and AI eras. Among the most experienced, and category-defining, are the company’s words. This desk did not rank investors, and it did not see the cap table, which is the list of who owns what.

The total, and what not to add. The round brings total capital raised since inception to more than $845 million. Inception means since the company started. More than $845 million is the pile after this round, on the company’s sentence. It already includes the $311 million. Do not add $311 million on top of $845 million and call the total $1.156 billion. The page does not print the earlier rounds one by one. Do not invent them.

What the platform is. Enveda calls itself a clinical-stage biotechnology company that uses AI to discover medicines from life’s chemistry. Clinical-stage means drugs are already in human studies. They are not approved products. The platform is PRISM, a proprietary AI foundation model trained on the chemistry of living organisms. Proprietary means the company owns it. A foundation model is a large AI model trained on a broad set of examples, then used for many related jobs. Here the examples are molecules living things already make. The page says PRISM does not design molecules from scratch. It identifies molecules that already exist in plants, microbes, and the human body, predicts their structures from mass spectrometry data, guides laboratory experiments to reveal what they do, and ranks them by therapeutic potential. Mass spectrometry is a lab method that weighs the pieces of a molecule so a computer can guess its structure. Enveda’s chemists then refine the most promising candidates into oral medicines, meaning pills, with drug-like properties. The company’s bet is that starting points shaped by evolution carry a lower risk of toxicity and of poor bioavailability than many synthetic molecules. Toxicity is harm. Bioavailability is how much of a swallowed drug actually reaches the blood. That lower risk is a bet. It is not a safety result this desk measured. The page says that since 2019 the approach has produced 17 development candidates, three of which are now in human trials, each with what the company calls a new, first-in-class mechanism. First-in-class, here, is the company’s label for a drug aimed at a target it says no approved drug hits yet. It is not an FDA designation this desk confirmed.

Three oral medicines in the clinic, in the page’s words. ENV-294 is a once-daily treatment for eczema and asthma that the company says helps calm overactive immune cells. Eczema is the common name. The same page also says atopic dermatitis, the clinical name for that rash. In a Phase 1b study, eczema severity improved by an average of 85 percent after 42 days, with no serious side effects. Phase 1b is an early human study, mainly about safety and a first look at whether the drug does something, in a small group. The page does not say how many people were in that 85 percent average. Do not invent a headcount. Phase 2 trials are underway. Phase 2 is the next study, in more people, to see whether that effect holds. The page says more data will be presented at the European Academy of Dermatology and Venereology Congress on 1 Oct 2026. ENV-308 is inspired by a natural molecule the body releases during intense exercise. It is being developed to help people maintain weight loss and metabolic health after they stop GLP-1 medicines. GLP-1 medicines are the drugs, many of them injections, that mimic a gut hormone and are widely used for weight loss. The page says ENV-308 was well tolerated in 88 healthy volunteers, with what it calls an exceptional gastrointestinal side-effect profile. Gastrointestinal means the stomach and the gut. The page notes those effects are among the most common reasons people stop GLP-1 medicines. Exceptional is the company’s adjective. The same trial showed that ENV-308 lowers circulating leptin, the hormone fat cells use to signal how much energy the body has stored. The page calls that an early sign the drug reaches the biology seen in animal studies of metabolic disease. The paragraph does not print the words Phase 1. The reference line on the same page calls the 18 Aug 2026 note “ENV-308 Phase 1 results.” File Phase 1 as that label. ENV-6946 is an oral treatment for inflammatory bowel disease that targets multiple inflammatory pathways at once and is now in Phase 1. Inflammatory bowel disease, shortened to IBD, is long-running inflammation of the gut. The page does not name a specific IBD diagnosis in that sentence. All three are investigational. The page says they are not approved for use by any regulatory authority. The page’s own warning says early or preclinical data may not predict later clinical results.

What the money is for, and who runs the company. Enveda says it will use the proceeds to advance ENV-294 and ENV-308 into later-stage trials and additional indications, with new trials expected to begin in the coming months; to advance ENV-6946 through mid-phase trials; to bring additional medicines into clinical trials, including for other inflammatory and metabolic conditions; and to keep scaling PRISM and the automated laboratory that feeds it. An indication is the disease a trial is allowed to study. Expected, and coming months, are a plan. They are not a start date this desk can put on a calendar. Viswa Colluru, Ph.D., is founder and chief executive. He said the drug industry has produced extraordinary medicines at a cost that keeps rising, and that Enveda started from a different premise: the most reliable source of new medicines is chemistry living things have been refining for billions of years, and AI finally lets the company read it. He said two novel molecules from that approach have shown early potential in people, and that this financing lets the company carry its own medicines from discovery through late-stage development, faster and at lower cost than the industry has come to accept. Faster, and lower cost, are his aim. They are not a clock or a bill this desk audited. The dateline is Boulder, Colo. The page footer prints 5700 Flatiron Parkway, Boulder, CO 80301.

Two older claims, still the company’s, not a literature review this desk redid. The page says nearly half of all oral medicines originate from molecules found in nature, and that an estimated 99 percent of nature’s chemical diversity has never been examined, because isolating and testing compounds from living organisms has been slow and expensive. It points at a 2020 paper by Newman and Cragg for that pair of sentences. Nearly half, and 99 percent, are the page’s figures. This desk did not re-count approved drugs. The page also says Alex Gorsky, a general partner at ICONIQ, co-founder of Alderline Group, and former chief executive of Johnson & Johnson, called the idea that evolution already ran the largest drug-discovery program, and that AI can now read it, the kind of idea ICONIQ viewed as having platform potential. He said the rate of pipeline progress and the early clinical data suggest the approach is working. Suggest, and we believe, are his. Over the past year the page says Enveda hired clinical leaders from Novo Nordisk, Madrigal Pharmaceuticals, and LEO Pharma: Nadeem Sarwar, Ph.D.; Michael Charlton, M.D.; and Doug Maslin. Those prior titles are the page’s. A hiring line is not a trial result.

Plain English for the rest of the card: Series E = a late private funding round. $311 million = this round, as the company states it closed. More than $845 million = all capital raised since the start, including this round, not a second pile on top. PRISM = Enveda’s AI model for molecules that already exist in living things. mass spectrometry = a lab weighing of a molecule’s pieces. Phase 1 = the first human study, mainly safety. Phase 1b = that early study, with a first look at effect. Phase 2 = the next study, in more people. 85 percent = the company’s average improvement in eczema severity at 42 days. The page does not say how many people that average covers. 88 = healthy volunteers in the ENV-308 study. GLP-1 = a gut-hormone drug used for weight loss. leptin = a hormone fat cells use to report stored energy. IBD = inflammatory bowel disease. investigational = not approved by a regulator. first-in-class = the company’s label, not an FDA prize this desk confirmed. This filing is the 23 Sep close. It is not an approval, and it is not a stock listing.

PRIMARY here: Enveda’s 23 Sep 2026 press page, “Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century,” at enveda.com — Tier A PRIMARY, the company’s own record. The page did not print an hour. BioSpace’s same-day press-release page is the wire syndication of that announcement, not a second set of numbers, and its Petrocheilos quote does not match the company page. The $311 million Series E, Catalio as lead, Petrocheilos joining the board, the new and existing investor names, the unnamed sovereign wealth fund, total capital of more than $845 million, the PRISM description, the ENV-294 85 percent figure and the missing headcount, Phase 2 underway, the 1 Oct 2026 congress line, the ENV-308 88 volunteers and the leptin line, the Phase 1 label on the ENV-308 reference, ENV-6946 in Phase 1, the use of proceeds, the Colluru title and quote, the 17 development candidates since 2019, the Gorsky roles, and the three clinical hires are the company page’s. The different Petrocheilos wording is BioSpace’s. NOT claimed: a valuation, a named sovereign fund, a patient count behind the 85 percent, that the two Petrocheilos quotes are one speech, that exceptional or faster and at lower cost was measured here, FDA approval, a Phase 1 sentence in the ENV-308 body paragraph beyond the reference label, that early data predicts a later trial, that this desk reviewed patient charts or a cap table, a stock tip, or investment advice. Distinct from the already-filed arpa-h-circle and iambic-s1-ipo.